News | October 25, 2023
Sumitomo Pharma announces authorization in Canada of Orgovyx for treatment prostate cancer
Orgovyx is the first and only oral GnRH receptor antagonist approved for advanced prostate cancer in Canada
Orgovyx is the first and only oral GnRH receptor antagonist approved for advanced prostate cancer in Canada
Three-point improvement achieved in Sex Ratio at Birth from 904 in 2017-19 to 907 in 2018-20
Approval of oral, once-daily VELSIPITY based on favorable safety and efficacy data from the ELEVATE UC Phase 3 trials
Merck to pay Daiichi Sankyo a $4 billion upfront payment in addition to $1.5 billion in continuation payments over the next 24 months
Profit after tax (before exceptional items) up 23% to Rs 215 crores
Glenmark's Zita portfolio of medicines have been benefiting around 1.75 million Type 2 diabetic patients annually
Glenmark's current portfolio consists of 188 products authorized for distribution in the US
Multi-million dollar investment augments in-vitro biology capabilities in primary and secondary screening
NexCAR19 is an indigenously developed CD19 targeted CAR-T cell therapy
The NDA filing for deuruxolitinib with the U.S. FDA is based on two pivotal Phase III trials
Subscribe To Our Newsletter & Stay Updated
